Efficacy of Adjunctive Treatments Added to Olanzapine or Clozapine for Weight Control in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

Table 2

Meta-analysis of topiramate ().

(a)

Number

First author

Concurrent therapy

Adjunctive agent; (mg/day, daily max. dose)

Duration (weeks)

(drop)

Primary outcome

Secondary outcome

Weight reduction

Mean outcome

Mean difference

Psychiatric evaluation

Mean baseline

Mean change

2

Narula (2010) [9]

Olanzapine

Topiramate (100); placebo

12

33 (3); 34 (2)

BMI (kg/m^2)

20.1; 22.6

0.004

PANSS

102.9; 103.8

−71.7; −70.5

0.001

3

Afshar (2009) [10]

Clozapine

Topiramate (300); placebo

8

16 (0); 16 (0)

BMI (kg/m^2)

23.2; 25.4

≤0.05

PANSS

96.9; 101.9

−20; −1.3

<0.001

(b)

Number	First author	Statistics for each study					Difference in means and 95% CI	Relative weight
		Difference in means	Standard error	Variance	value	value
2; 3	Narula (2010) [9]; Afshar (2009) [10]; Total	−2.500; −2.190; −2.405	0.990; 1.491; 0.825	0.980; 2.223; 0.680	−2.525; −1.469; −2.916	0.012; 0.142; 0.004		69.41; 30.59; 100.00

Heterogeneity: ; df = 1; ; = 0.00.